We are a patient-centric, clinical-stage biopharmaceutical company dedicated to bringing etripamil to patients living with paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation (AFib), as well as other episodic cardiovascular conditions.
Over the past decade, Milestone has assembled a panel of leading pharmaceutical executives with many years of experience in drug research and development.
Since our founding, our unwavering focus has been on developing treatment solutions based on clinically-validated mechanisms of action that can be self-administered by the patient.
Our approach minimizes overhead and focuses spending on what matters most: developing treatment solutions that fill an unmet need and alleviating current treatment burdens for patients and their families living with episodic cardiovascular conditions.
Our core leadership team brings extensive expertise in cardiovascular medicine, clinical drug development, regulatory affairs and quality assurance, manufacturing, and commercialization preparedness.
At Milestone, everything we do is with the patient in mind. To that end, we partner with groups and organizations who share our dedication to support and educate people with episodic cardiovascular conditions. We created OutsmartPSVT.com, the first website devoted to helping patients and caregivers manage PSVT, in partnership with their healthcare team.
Milestone is committed to improving the lives of people living with cardiovascular conditions. For more than a decade, Milestone has been developing etripamil, which is intended to empower patients to terminate their SVT episodes or control their AFib by self-treating their episodes wherever and whenever they occur.
Milestone is committed to improving the lives of people living with cardiovascular and cardiovascular-related conditions. For more than a decade, Milestone has been developing etripamil, which is intended to terminate SVT episodes wherever they occur when self-administered by patients with PSVT.